Pivotal bioVenture Partners Investment Advisor LLC

CIK 0001844645 · SAN FRANCISCO, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source

Pivotal bioVenture Partners Investment Advisor LLC reported 13 positions worth $307.8M as of June 30, 2026 (13F filed August 13, 2026). Largest holding: PCVX (26.9%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$307.8M
2026 Q2
Positions
13
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
95.1%
Est. Net Flow (Q)
2026 Q2
10 / 13 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1PCVXVAXCYTE INCSH$82.9M26.92%1,425,470
2ARQTARCUTIS BIOTHERAPEUTICS INCSH$33.2M10.78%1,265,283
3TRVITREVI THERAPEUTICS INCSH$32.5M10.56%1,742,672
4AVLNAVALYN PHARMACEUTICALS INCSH$31.8M10.34%966,792
5EVMNEVOMMUNE INCSH$25.6M8.32%1,926,943
6MPLTMAPLIGHT THERAPEUTICS INCSH$21.9M7.12%611,446
7OCSOCULIS HOLDING AGSH$20.9M6.79%1,506,250
8BIOABIOAGE LABS INCSH$16.0M5.20%653,374
9IMNMIMMUNOME INCSH$15.5M5.04%732,512
10ZBIOZENAS BIOPHARMA INCSH$12.5M4.05%490,766

The free plan shows the top 10 positions. The remaining 3 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Pivotal bioVenture Partners Investment Advisor LLC hold as of Q2 2026?

Pivotal bioVenture Partners Investment Advisor LLC reported 13 positions worth $307.8M in its Q2 2026 13F filing. Largest positions: PCVX (26.9%), ARQT (10.8%), TRVI (10.6%), AVLN (10.3%) and EVMN (8.3%).

What did Pivotal bioVenture Partners Investment Advisor LLC buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Pivotal bioVenture Partners Investment Advisor LLC sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.